1	1	_	_	_	_	_	_	_	_
2	.	_	_	_	_	_	_	_	_


1	Introduction	_	_	_	_	_	_	_	_


1	Extracellular	_	_	_	_	_	_	_	_
2	vesicles	_	_	_	_	_	_	_	_
3	(	_	_	_	_	_	_	_	_
4	EVs	_	_	_	_	_	_	_	_
5	)	_	_	_	_	_	_	_	_
6	are	_	_	_	_	_	_	_	_
7	cell-derived	_	_	_	_	_	_	_	_
8	membrane	_	_	_	_	_	_	_	_
9	vesicles	_	_	_	_	_	_	_	_
10	that	_	_	_	_	_	_	_	_
11	represent	_	_	_	_	_	_	_	_
12	an	_	_	_	_	_	_	_	_
13	endogenous	_	_	_	_	_	_	_	_
14	mechanism	_	_	_	_	_	_	_	_
15	for	_	_	_	_	_	_	_	_
16	intercellular	_	_	_	_	_	_	_	_
17	communication	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	EVs	_	_	_	_	_	_	_	_
2	can	_	_	_	_	_	_	_	_
3	be	_	_	_	_	_	_	_	_
4	classified	_	_	_	_	_	_	_	_
5	in	_	_	_	_	_	_	_	_
6	exosomes	_	_	_	_	_	_	_	_
7	,	_	_	_	_	_	_	_	_
8	nano-sized	_	_	_	_	_	_	_	_
9	vesicles	_	_	_	_	_	_	_	_
10	(	_	_	_	_	_	_	_	_
11	with	_	_	_	_	_	_	_	_
12	a	_	_	_	_	_	_	_	_
13	diameter	_	_	_	_	_	_	_	_
14	in	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	range	_	_	_	_	_	_	_	_
17	of	_	_	_	_	_	_	_	_
18	30	_	_	_	_	_	_	_	_
19	to	_	_	_	_	_	_	_	_
20	120	_	_	_	_	_	_	_	_
21	nm	_	_	_	_	_	_	_	_
22	)	_	_	_	_	_	_	_	_
23	,	_	_	_	_	_	_	_	_
24	that	_	_	_	_	_	_	_	_
25	originate	_	_	_	_	_	_	_	_
26	from	_	_	_	_	_	_	_	_
27	the	_	_	_	_	_	_	_	_
28	cell	_	_	_	_	_	_	_	_
29	endocytic	_	_	_	_	_	_	_	_
30	compartment	_	_	_	_	_	_	_	_
31	through	_	_	_	_	_	_	_	_
32	the	_	_	_	_	_	_	_	_
33	formation	_	_	_	_	_	_	_	_
34	of	_	_	_	_	_	_	_	_
35	multivesicular	_	_	_	_	_	_	_	_
36	bodies	_	_	_	_	_	_	_	_
37	(	_	_	_	_	_	_	_	_
38	MVB	_	_	_	_	_	_	_	_
39	)	_	_	_	_	_	_	_	_
40	,	_	_	_	_	_	_	_	_
41	microvesicles	_	_	_	_	_	_	_	_
42	,	_	_	_	_	_	_	_	_
43	with	_	_	_	_	_	_	_	_
44	a	_	_	_	_	_	_	_	_
45	diameter	_	_	_	_	_	_	_	_
46	up	_	_	_	_	_	_	_	_
47	to	_	_	_	_	_	_	_	_
48	1	_	_	_	_	_	_	_	_
49	μm	_	_	_	_	_	_	_	_
50	released	_	_	_	_	_	_	_	_
51	by	_	_	_	_	_	_	_	_
52	cell	_	_	_	_	_	_	_	_
53	membrane	_	_	_	_	_	_	_	_
54	budding	_	_	_	_	_	_	_	_
55	,	_	_	_	_	_	_	_	_
56	and	_	_	_	_	_	_	_	_
57	apoptotic	_	_	_	_	_	_	_	_
58	bodies	_	_	_	_	_	_	_	_
59	,	_	_	_	_	_	_	_	_
60	with	_	_	_	_	_	_	_	_
61	a	_	_	_	_	_	_	_	_
62	dimension	_	_	_	_	_	_	_	_
63	similar	_	_	_	_	_	_	_	_
64	to	_	_	_	_	_	_	_	_
65	platelets	_	_	_	_	_	_	_	_
66	,	_	_	_	_	_	_	_	_
67	derived	_	_	_	_	_	_	_	_
68	from	_	_	_	_	_	_	_	_
69	blebbing	_	_	_	_	_	_	_	_
70	of	_	_	_	_	_	_	_	_
71	dying	_	_	_	_	_	_	_	_
72	cells	_	_	_	_	_	_	_	_
73	.	_	_	_	_	_	_	_	_


1	Despite	_	_	_	_	_	_	_	_
2	the	_	_	_	_	_	_	_	_
3	distinct	_	_	_	_	_	_	_	_
4	sizes	_	_	_	_	_	_	_	_
5	and	_	_	_	_	_	_	_	_
6	biogenesis	_	_	_	_	_	_	_	_
7	,	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	absence	_	_	_	_	_	_	_	_
10	of	_	_	_	_	_	_	_	_
11	standardized	_	_	_	_	_	_	_	_
12	isolation	_	_	_	_	_	_	_	_
13	methods	_	_	_	_	_	_	_	_
14	and	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	numerous	_	_	_	_	_	_	_	_
17	similarities	_	_	_	_	_	_	_	_
18	existing	_	_	_	_	_	_	_	_
19	between	_	_	_	_	_	_	_	_
20	these	_	_	_	_	_	_	_	_
21	two	_	_	_	_	_	_	_	_
22	subclasses	_	_	_	_	_	_	_	_
23	make	_	_	_	_	_	_	_	_
24	it	_	_	_	_	_	_	_	_
25	particularly	_	_	_	_	_	_	_	_
26	challenging	_	_	_	_	_	_	_	_
27	to	_	_	_	_	_	_	_	_
28	distinguish	_	_	_	_	_	_	_	_
29	among	_	_	_	_	_	_	_	_
30	them	_	_	_	_	_	_	_	_
31	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	this	_	_	_	_	_	_	_	_
3	review	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	we	_	_	_	_	_	_	_	_
6	will	_	_	_	_	_	_	_	_
7	use	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	generic	_	_	_	_	_	_	_	_
10	term	_	_	_	_	_	_	_	_
11	EVs	_	_	_	_	_	_	_	_
12	to	_	_	_	_	_	_	_	_
13	indicate	_	_	_	_	_	_	_	_
14	both	_	_	_	_	_	_	_	_
15	exosomes	_	_	_	_	_	_	_	_
16	and	_	_	_	_	_	_	_	_
17	microvesicles	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	EVs	_	_	_	_	_	_	_	_
2	have	_	_	_	_	_	_	_	_
3	been	_	_	_	_	_	_	_	_
4	shown	_	_	_	_	_	_	_	_
5	to	_	_	_	_	_	_	_	_
6	carry	_	_	_	_	_	_	_	_
7	functionally	_	_	_	_	_	_	_	_
8	active	_	_	_	_	_	_	_	_
9	biological	_	_	_	_	_	_	_	_
10	materials	_	_	_	_	_	_	_	_
11	including	_	_	_	_	_	_	_	_
12	proteins	_	_	_	_	_	_	_	_
13	,	_	_	_	_	_	_	_	_
14	mRNAs	_	_	_	_	_	_	_	_
15	and	_	_	_	_	_	_	_	_
16	miRNAs	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	which	_	_	_	_	_	_	_	_
19	makes	_	_	_	_	_	_	_	_
20	them	_	_	_	_	_	_	_	_
21	capable	_	_	_	_	_	_	_	_
22	of	_	_	_	_	_	_	_	_
23	transmitting	_	_	_	_	_	_	_	_
24	signals	_	_	_	_	_	_	_	_
25	to	_	_	_	_	_	_	_	_
26	target	_	_	_	_	_	_	_	_
27	cells	_	_	_	_	_	_	_	_
28	in	_	_	_	_	_	_	_	_
29	the	_	_	_	_	_	_	_	_
30	surrounding	_	_	_	_	_	_	_	_
31	environment	_	_	_	_	_	_	_	_
32	as	_	_	_	_	_	_	_	_
33	well	_	_	_	_	_	_	_	_
34	as	_	_	_	_	_	_	_	_
35	to	_	_	_	_	_	_	_	_
36	distant	_	_	_	_	_	_	_	_
37	organs	_	_	_	_	_	_	_	_
38	,	_	_	_	_	_	_	_	_
39	via	_	_	_	_	_	_	_	_
40	blood	_	_	_	_	_	_	_	_
41	and	_	_	_	_	_	_	_	_
42	lymphatic	_	_	_	_	_	_	_	_
43	vessels	_	_	_	_	_	_	_	_
44	.	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	scientific	_	_	_	_	_	_	_	_
3	community	_	_	_	_	_	_	_	_
4	has	_	_	_	_	_	_	_	_
5	recently	_	_	_	_	_	_	_	_
6	turned	_	_	_	_	_	_	_	_
7	its	_	_	_	_	_	_	_	_
8	interest	_	_	_	_	_	_	_	_
9	toward	_	_	_	_	_	_	_	_
10	the	_	_	_	_	_	_	_	_
11	evaluation	_	_	_	_	_	_	_	_
12	of	_	_	_	_	_	_	_	_
13	EVs	_	_	_	_	_	_	_	_
14	as	_	_	_	_	_	_	_	_
15	drug	_	_	_	_	_	_	_	_
16	delivery	_	_	_	_	_	_	_	_
17	vehicles	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	this	_	_	_	_	_	_	_	_
3	context	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	EVs	_	_	_	_	_	_	_	_
6	offer	_	_	_	_	_	_	_	_
7	significant	_	_	_	_	_	_	_	_
8	advantages	_	_	_	_	_	_	_	_
9	over	_	_	_	_	_	_	_	_
10	current	_	_	_	_	_	_	_	_
11	drug	_	_	_	_	_	_	_	_
12	delivery	_	_	_	_	_	_	_	_
13	systems	_	_	_	_	_	_	_	_
14	,	_	_	_	_	_	_	_	_
15	such	_	_	_	_	_	_	_	_
16	as	_	_	_	_	_	_	_	_
17	liposomes	_	_	_	_	_	_	_	_
18	and	_	_	_	_	_	_	_	_
19	polymeric	_	_	_	_	_	_	_	_
20	nanoparticles	_	_	_	_	_	_	_	_
21	.	_	_	_	_	_	_	_	_


1	Since	_	_	_	_	_	_	_	_
2	EVs	_	_	_	_	_	_	_	_
3	can	_	_	_	_	_	_	_	_
4	be	_	_	_	_	_	_	_	_
5	obtained	_	_	_	_	_	_	_	_
6	with	_	_	_	_	_	_	_	_
7	an	_	_	_	_	_	_	_	_
8	autologous	_	_	_	_	_	_	_	_
9	procedure	_	_	_	_	_	_	_	_
10	from	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	patient	_	_	_	_	_	_	_	_
13	’s	_	_	_	_	_	_	_	_
14	cells	_	_	_	_	_	_	_	_
15	or	_	_	_	_	_	_	_	_
16	blood	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	they	_	_	_	_	_	_	_	_
19	do	_	_	_	_	_	_	_	_
20	not	_	_	_	_	_	_	_	_
21	solicit	_	_	_	_	_	_	_	_
22	the	_	_	_	_	_	_	_	_
23	immune	_	_	_	_	_	_	_	_
24	system	_	_	_	_	_	_	_	_
25	as	_	_	_	_	_	_	_	_
26	usual	_	_	_	_	_	_	_	_
27	synthetic	_	_	_	_	_	_	_	_
28	formulations	_	_	_	_	_	_	_	_
29	do	_	_	_	_	_	_	_	_
30	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	addition	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	given	_	_	_	_	_	_	_	_
5	their	_	_	_	_	_	_	_	_
6	phospholipid	_	_	_	_	_	_	_	_
7	bilayer	_	_	_	_	_	_	_	_
8	,	_	_	_	_	_	_	_	_
9	EVs	_	_	_	_	_	_	_	_
10	can	_	_	_	_	_	_	_	_
11	directly	_	_	_	_	_	_	_	_
12	fuse	_	_	_	_	_	_	_	_
13	with	_	_	_	_	_	_	_	_
14	the	_	_	_	_	_	_	_	_
15	targeted	_	_	_	_	_	_	_	_
16	plasma	_	_	_	_	_	_	_	_
17	membrane	_	_	_	_	_	_	_	_
18	,	_	_	_	_	_	_	_	_
19	thus	_	_	_	_	_	_	_	_
20	allowing	_	_	_	_	_	_	_	_
21	a	_	_	_	_	_	_	_	_
22	more	_	_	_	_	_	_	_	_
23	efficient	_	_	_	_	_	_	_	_
24	internalization	_	_	_	_	_	_	_	_
25	of	_	_	_	_	_	_	_	_
26	the	_	_	_	_	_	_	_	_
27	encapsulated	_	_	_	_	_	_	_	_
28	drug	_	_	_	_	_	_	_	_
29	.	_	_	_	_	_	_	_	_
30	Their	_	_	_	_	_	_	_	_
31	hydrophilic	_	_	_	_	_	_	_	_
32	shell	_	_	_	_	_	_	_	_
33	,	_	_	_	_	_	_	_	_
34	together	_	_	_	_	_	_	_	_
35	with	_	_	_	_	_	_	_	_
36	the	_	_	_	_	_	_	_	_
37	presence	_	_	_	_	_	_	_	_
38	of	_	_	_	_	_	_	_	_
39	anti-phagocytosis	_	_	_	_	_	_	_	_
40	surface	_	_	_	_	_	_	_	_
41	markers	_	_	_	_	_	_	_	_
42	(	_	_	_	_	_	_	_	_
43	i.	_	_	_	_	_	_	_	_
44	e.	_	_	_	_	_	_	_	_
45	,	_	_	_	_	_	_	_	_
46	CD47	_	_	_	_	_	_	_	_
47	)	_	_	_	_	_	_	_	_
48	,	_	_	_	_	_	_	_	_
49	enables	_	_	_	_	_	_	_	_
50	them	_	_	_	_	_	_	_	_
51	to	_	_	_	_	_	_	_	_
52	evade	_	_	_	_	_	_	_	_
53	phagocytosis	_	_	_	_	_	_	_	_
54	by	_	_	_	_	_	_	_	_
55	monocytes	_	_	_	_	_	_	_	_
56	and	_	_	_	_	_	_	_	_
57	macrophages	_	_	_	_	_	_	_	_
58	of	_	_	_	_	_	_	_	_
59	the	_	_	_	_	_	_	_	_
60	reticulo-endothelial	_	_	_	_	_	_	_	_
61	system	_	_	_	_	_	_	_	_
62	,	_	_	_	_	_	_	_	_
63	hence	_	_	_	_	_	_	_	_
64	weakening	_	_	_	_	_	_	_	_
65	their	_	_	_	_	_	_	_	_
66	clearance	_	_	_	_	_	_	_	_
67	.	_	_	_	_	_	_	_	_


1	Moreover	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	limited	_	_	_	_	_	_	_	_
5	size	_	_	_	_	_	_	_	_
6	allows	_	_	_	_	_	_	_	_
7	them	_	_	_	_	_	_	_	_
8	to	_	_	_	_	_	_	_	_
9	efficiently	_	_	_	_	_	_	_	_
10	extravasate	_	_	_	_	_	_	_	_
11	through	_	_	_	_	_	_	_	_
12	the	_	_	_	_	_	_	_	_
13	inter-endothelial	_	_	_	_	_	_	_	_
14	junctions	_	_	_	_	_	_	_	_
15	and	_	_	_	_	_	_	_	_
16	fenestrations	_	_	_	_	_	_	_	_
17	of	_	_	_	_	_	_	_	_
18	both	_	_	_	_	_	_	_	_
19	existing	_	_	_	_	_	_	_	_
20	and	_	_	_	_	_	_	_	_
21	neo-synthesized	_	_	_	_	_	_	_	_
22	vessels	_	_	_	_	_	_	_	_
23	.	_	_	_	_	_	_	_	_


1	Thanks	_	_	_	_	_	_	_	_
2	to	_	_	_	_	_	_	_	_
3	these	_	_	_	_	_	_	_	_
4	peculiar	_	_	_	_	_	_	_	_
5	characteristics	_	_	_	_	_	_	_	_
6	,	_	_	_	_	_	_	_	_
7	they	_	_	_	_	_	_	_	_
8	can	_	_	_	_	_	_	_	_
9	spread	_	_	_	_	_	_	_	_
10	and	_	_	_	_	_	_	_	_
11	accumulate	_	_	_	_	_	_	_	_
12	in	_	_	_	_	_	_	_	_
13	the	_	_	_	_	_	_	_	_
14	parenchyma	_	_	_	_	_	_	_	_
15	of	_	_	_	_	_	_	_	_
16	solid	_	_	_	_	_	_	_	_
17	tumors	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	EV	_	_	_	_	_	_	_	_
2	biological	_	_	_	_	_	_	_	_
3	properties	_	_	_	_	_	_	_	_
4	derive	_	_	_	_	_	_	_	_
5	from	_	_	_	_	_	_	_	_
6	their	_	_	_	_	_	_	_	_
7	sophisticated	_	_	_	_	_	_	_	_
8	membrane	_	_	_	_	_	_	_	_
9	structure	_	_	_	_	_	_	_	_
10	,	_	_	_	_	_	_	_	_
11	characterized	_	_	_	_	_	_	_	_
12	by	_	_	_	_	_	_	_	_
13	the	_	_	_	_	_	_	_	_
14	presence	_	_	_	_	_	_	_	_
15	of	_	_	_	_	_	_	_	_
16	several	_	_	_	_	_	_	_	_
17	proteins	_	_	_	_	_	_	_	_
18	for	_	_	_	_	_	_	_	_
19	active	_	_	_	_	_	_	_	_
20	targeting	_	_	_	_	_	_	_	_
21	,	_	_	_	_	_	_	_	_
22	adhesion	_	_	_	_	_	_	_	_
23	,	_	_	_	_	_	_	_	_
24	cell	_	_	_	_	_	_	_	_
25	fusion	_	_	_	_	_	_	_	_
26	,	_	_	_	_	_	_	_	_
27	and	_	_	_	_	_	_	_	_
28	intracellular	_	_	_	_	_	_	_	_
29	release	_	_	_	_	_	_	_	_
30	of	_	_	_	_	_	_	_	_
31	their	_	_	_	_	_	_	_	_
32	content	_	_	_	_	_	_	_	_
33	;	_	_	_	_	_	_	_	_
34	this	_	_	_	_	_	_	_	_
35	functional	_	_	_	_	_	_	_	_
36	complexity	_	_	_	_	_	_	_	_
37	is	_	_	_	_	_	_	_	_
38	not	_	_	_	_	_	_	_	_
39	easily	_	_	_	_	_	_	_	_
40	reproduced	_	_	_	_	_	_	_	_
41	by	_	_	_	_	_	_	_	_
42	de	_	_	_	_	_	_	_	_
43	novo	_	_	_	_	_	_	_	_
44	synthesized	_	_	_	_	_	_	_	_
45	nanoparticles	_	_	_	_	_	_	_	_
46	.	_	_	_	_	_	_	_	_


1	Among	_	_	_	_	_	_	_	_
2	the	_	_	_	_	_	_	_	_
3	several	_	_	_	_	_	_	_	_
4	types	_	_	_	_	_	_	_	_
5	of	_	_	_	_	_	_	_	_
6	nano-based	_	_	_	_	_	_	_	_
7	drug	_	_	_	_	_	_	_	_
8	delivery	_	_	_	_	_	_	_	_
9	systems	_	_	_	_	_	_	_	_
10	,	_	_	_	_	_	_	_	_
11	liposomes	_	_	_	_	_	_	_	_
12	are	_	_	_	_	_	_	_	_
13	probably	_	_	_	_	_	_	_	_
14	the	_	_	_	_	_	_	_	_
15	most	_	_	_	_	_	_	_	_
16	used	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	due	_	_	_	_	_	_	_	_
19	to	_	_	_	_	_	_	_	_
20	their	_	_	_	_	_	_	_	_
21	non-toxicity	_	_	_	_	_	_	_	_
22	and	_	_	_	_	_	_	_	_
23	capacity	_	_	_	_	_	_	_	_
24	to	_	_	_	_	_	_	_	_
25	accommodate	_	_	_	_	_	_	_	_
26	high	_	_	_	_	_	_	_	_
27	amounts	_	_	_	_	_	_	_	_
28	of	_	_	_	_	_	_	_	_
29	compounds	_	_	_	_	_	_	_	_
30	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	a	_	_	_	_	_	_	_	_
4	still	_	_	_	_	_	_	_	_
5	inadequate	_	_	_	_	_	_	_	_
6	in	_	_	_	_	_	_	_	_
7	vivo	_	_	_	_	_	_	_	_
8	targeting	_	_	_	_	_	_	_	_
9	efficiency	_	_	_	_	_	_	_	_
10	together	_	_	_	_	_	_	_	_
11	with	_	_	_	_	_	_	_	_
12	a	_	_	_	_	_	_	_	_
13	potential	_	_	_	_	_	_	_	_
14	immunogenicity	_	_	_	_	_	_	_	_
15	associated	_	_	_	_	_	_	_	_
16	to	_	_	_	_	_	_	_	_
17	liposomal	_	_	_	_	_	_	_	_
18	formulations	_	_	_	_	_	_	_	_
19	has	_	_	_	_	_	_	_	_
20	limited	_	_	_	_	_	_	_	_
21	their	_	_	_	_	_	_	_	_
22	broad	_	_	_	_	_	_	_	_
23	applicability	_	_	_	_	_	_	_	_
24	in	_	_	_	_	_	_	_	_
25	therapeutics	_	_	_	_	_	_	_	_
26	.	_	_	_	_	_	_	_	_


1	Therefore	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	greater	_	_	_	_	_	_	_	_
5	specificity	_	_	_	_	_	_	_	_
6	combined	_	_	_	_	_	_	_	_
7	with	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	consequent	_	_	_	_	_	_	_	_
10	limited	_	_	_	_	_	_	_	_
11	induction	_	_	_	_	_	_	_	_
12	of	_	_	_	_	_	_	_	_
13	systemic	_	_	_	_	_	_	_	_
14	side	_	_	_	_	_	_	_	_
15	effects	_	_	_	_	_	_	_	_
16	make	_	_	_	_	_	_	_	_
17	EVs	_	_	_	_	_	_	_	_
18	ideal	_	_	_	_	_	_	_	_
19	vehicles	_	_	_	_	_	_	_	_
20	for	_	_	_	_	_	_	_	_
21	drug	_	_	_	_	_	_	_	_
22	delivery	_	_	_	_	_	_	_	_
23	.	_	_	_	_	_	_	_	_


1	Although	_	_	_	_	_	_	_	_
2	this	_	_	_	_	_	_	_	_
3	research	_	_	_	_	_	_	_	_
4	field	_	_	_	_	_	_	_	_
5	is	_	_	_	_	_	_	_	_
6	in	_	_	_	_	_	_	_	_
7	its	_	_	_	_	_	_	_	_
8	infancy	_	_	_	_	_	_	_	_
9	,	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	last	_	_	_	_	_	_	_	_
13	decade	_	_	_	_	_	_	_	_
14	,	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	use	_	_	_	_	_	_	_	_
17	of	_	_	_	_	_	_	_	_
18	bio-engineered	_	_	_	_	_	_	_	_
19	EVs	_	_	_	_	_	_	_	_
20	for	_	_	_	_	_	_	_	_
21	the	_	_	_	_	_	_	_	_
22	delivery	_	_	_	_	_	_	_	_
23	of	_	_	_	_	_	_	_	_
24	cytotoxic	_	_	_	_	_	_	_	_
25	molecules	_	_	_	_	_	_	_	_
26	in	_	_	_	_	_	_	_	_
27	preclinical	_	_	_	_	_	_	_	_
28	models	_	_	_	_	_	_	_	_
29	has	_	_	_	_	_	_	_	_
30	produced	_	_	_	_	_	_	_	_
31	encouraging	_	_	_	_	_	_	_	_
32	results	_	_	_	_	_	_	_	_
33	.	_	_	_	_	_	_	_	_


1	These	_	_	_	_	_	_	_	_
2	experimental	_	_	_	_	_	_	_	_
3	evidences	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	in	_	_	_	_	_	_	_	_
6	addition	_	_	_	_	_	_	_	_
7	to	_	_	_	_	_	_	_	_
8	preliminary	_	_	_	_	_	_	_	_
9	clinical	_	_	_	_	_	_	_	_
10	data	_	_	_	_	_	_	_	_
11	,	_	_	_	_	_	_	_	_
12	indicate	_	_	_	_	_	_	_	_
13	that	_	_	_	_	_	_	_	_
14	EV	_	_	_	_	_	_	_	_
15	formulations	_	_	_	_	_	_	_	_
16	may	_	_	_	_	_	_	_	_
17	not	_	_	_	_	_	_	_	_
18	only	_	_	_	_	_	_	_	_
19	enhance	_	_	_	_	_	_	_	_
20	the	_	_	_	_	_	_	_	_
21	safety	_	_	_	_	_	_	_	_
22	and	_	_	_	_	_	_	_	_
23	biodistribution	_	_	_	_	_	_	_	_
24	of	_	_	_	_	_	_	_	_
25	commonly	_	_	_	_	_	_	_	_
26	used	_	_	_	_	_	_	_	_
27	drugs	_	_	_	_	_	_	_	_
28	,	_	_	_	_	_	_	_	_
29	but	_	_	_	_	_	_	_	_
30	also	_	_	_	_	_	_	_	_
31	increase	_	_	_	_	_	_	_	_
32	their	_	_	_	_	_	_	_	_
33	efficacy	_	_	_	_	_	_	_	_
34	.	_	_	_	_	_	_	_	_


1	For	_	_	_	_	_	_	_	_
2	example	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	it	_	_	_	_	_	_	_	_
5	has	_	_	_	_	_	_	_	_
6	been	_	_	_	_	_	_	_	_
7	demonstrated	_	_	_	_	_	_	_	_
8	that	_	_	_	_	_	_	_	_
9	the	_	_	_	_	_	_	_	_
10	administration	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	EV-encapsulating	_	_	_	_	_	_	_	_
13	chemotherapy	_	_	_	_	_	_	_	_
14	drugs	_	_	_	_	_	_	_	_
15	leads	_	_	_	_	_	_	_	_
16	to	_	_	_	_	_	_	_	_
17	a	_	_	_	_	_	_	_	_
18	significant	_	_	_	_	_	_	_	_
19	reduction	_	_	_	_	_	_	_	_
20	of	_	_	_	_	_	_	_	_
21	drug	_	_	_	_	_	_	_	_
22	accumulation	_	_	_	_	_	_	_	_
23	in	_	_	_	_	_	_	_	_
24	off-target	_	_	_	_	_	_	_	_
25	organs	_	_	_	_	_	_	_	_
26	,	_	_	_	_	_	_	_	_
27	thus	_	_	_	_	_	_	_	_
28	preventing	_	_	_	_	_	_	_	_
29	important	_	_	_	_	_	_	_	_
30	side	_	_	_	_	_	_	_	_
31	effects	_	_	_	_	_	_	_	_
32	during	_	_	_	_	_	_	_	_
33	standard	_	_	_	_	_	_	_	_
34	clinical	_	_	_	_	_	_	_	_
35	protocols	_	_	_	_	_	_	_	_
36	.	_	_	_	_	_	_	_	_


1	An	_	_	_	_	_	_	_	_
2	astonishing	_	_	_	_	_	_	_	_
3	number	_	_	_	_	_	_	_	_
4	of	_	_	_	_	_	_	_	_
5	newly	_	_	_	_	_	_	_	_
6	published	_	_	_	_	_	_	_	_
7	papers	_	_	_	_	_	_	_	_
8	perfectly	_	_	_	_	_	_	_	_
9	depict	_	_	_	_	_	_	_	_
10	the	_	_	_	_	_	_	_	_
11	scientific	_	_	_	_	_	_	_	_
12	community	_	_	_	_	_	_	_	_
13	’s	_	_	_	_	_	_	_	_
14	authentic	_	_	_	_	_	_	_	_
15	interest	_	_	_	_	_	_	_	_
16	in	_	_	_	_	_	_	_	_
17	this	_	_	_	_	_	_	_	_
18	flourishing	_	_	_	_	_	_	_	_
19	research	_	_	_	_	_	_	_	_
20	field	_	_	_	_	_	_	_	_
21	.	_	_	_	_	_	_	_	_


1	Nevertheless	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	first	_	_	_	_	_	_	_	_
5	aim	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	this	_	_	_	_	_	_	_	_
8	review	_	_	_	_	_	_	_	_
9	is	_	_	_	_	_	_	_	_
10	to	_	_	_	_	_	_	_	_
11	disclose	_	_	_	_	_	_	_	_
12	an	_	_	_	_	_	_	_	_
13	overview	_	_	_	_	_	_	_	_
14	of	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	latest	_	_	_	_	_	_	_	_
17	applications	_	_	_	_	_	_	_	_
18	of	_	_	_	_	_	_	_	_
19	EVs	_	_	_	_	_	_	_	_
20	as	_	_	_	_	_	_	_	_
21	drug	_	_	_	_	_	_	_	_
22	delivery	_	_	_	_	_	_	_	_
23	vehicles	_	_	_	_	_	_	_	_
24	,	_	_	_	_	_	_	_	_
25	focusing	_	_	_	_	_	_	_	_
26	on	_	_	_	_	_	_	_	_
27	the	_	_	_	_	_	_	_	_
28	sources	_	_	_	_	_	_	_	_
29	employed	_	_	_	_	_	_	_	_
30	,	_	_	_	_	_	_	_	_
31	the	_	_	_	_	_	_	_	_
32	molecules	_	_	_	_	_	_	_	_
33	selected	_	_	_	_	_	_	_	_
34	,	_	_	_	_	_	_	_	_
35	and	_	_	_	_	_	_	_	_
36	the	_	_	_	_	_	_	_	_
37	final	_	_	_	_	_	_	_	_
38	intended	_	_	_	_	_	_	_	_
39	targets	_	_	_	_	_	_	_	_
40	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	the	_	_	_	_	_	_	_	_
3	second	_	_	_	_	_	_	_	_
4	part	_	_	_	_	_	_	_	_
5	of	_	_	_	_	_	_	_	_
6	the	_	_	_	_	_	_	_	_
7	review	_	_	_	_	_	_	_	_
8	,	_	_	_	_	_	_	_	_
9	we	_	_	_	_	_	_	_	_
10	will	_	_	_	_	_	_	_	_
11	take	_	_	_	_	_	_	_	_
12	a	_	_	_	_	_	_	_	_
13	step	_	_	_	_	_	_	_	_
14	back	_	_	_	_	_	_	_	_
15	and	_	_	_	_	_	_	_	_
16	bring	_	_	_	_	_	_	_	_
17	attention	_	_	_	_	_	_	_	_
18	to	_	_	_	_	_	_	_	_
19	the	_	_	_	_	_	_	_	_
20	basics	_	_	_	_	_	_	_	_
21	of	_	_	_	_	_	_	_	_
22	one	_	_	_	_	_	_	_	_
23	of	_	_	_	_	_	_	_	_
24	the	_	_	_	_	_	_	_	_
25	main	_	_	_	_	_	_	_	_
26	pitfalls	_	_	_	_	_	_	_	_
27	concerning	_	_	_	_	_	_	_	_
28	EVs	_	_	_	_	_	_	_	_
29	:	_	_	_	_	_	_	_	_
30	the	_	_	_	_	_	_	_	_
31	urgent	_	_	_	_	_	_	_	_
32	need	_	_	_	_	_	_	_	_
33	for	_	_	_	_	_	_	_	_
34	highly	_	_	_	_	_	_	_	_
35	pure	_	_	_	_	_	_	_	_
36	vesicle	_	_	_	_	_	_	_	_
37	preparation	_	_	_	_	_	_	_	_
38	.	_	_	_	_	_	_	_	_

